Back to today’s briefing

Story perspectives

Semaglutide Users Face 32% Increased Risk of Vision Loss

2/25/2025

45 6

Summary

Story summary

A groundbreaking study by Dr. Cindy X. Cal has uncovered a startling 32% rise in the risk of non-arteritic anterior ischemic optic neuropathy (NAION) for new semaglutide users. As concerns mount, thousands are taking legal action against Novo Nordisk, alleging negligence over safety issues linked to gastrointestinal problems and vision loss.

1 of 1

Story summary

A groundbreaking study by Dr. Cindy X. Cal has uncovered a startling 32% rise in the risk of non-arteritic anterior ischemic optic neuropathy (NAION) for new semaglutide users. As concerns mount, thousands are taking legal action against Novo Nordisk, alleging negligence over safety issues linked to gastrointestinal problems and vision loss.